Growth hormone: Challenges and opportunities for the biotechnology sector

Journal of Anti-Aging Medicine

Volumn 5, Issue 1, 2002, Pages 57-62

  Hathaway, David R ^a  

^a Restoragen Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; GROWTH HORMONE RELEASING PEPTIDE; SOMATOMEDIN C; UNCLASSIFIED DRUG;

BIOTECHNOLOGY; DISEASE MARKER; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; HUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0036090679     PISSN: 10945458     EISSN: None     Source Type: Journal    
DOI: 10.1089/109454502317629291     Document Type: Review

References (35)

1. Educating patients about the benefits and drawbacks of hormone replacement therapy
2. The Colorado Thyroid Disease Prevalence Study
3. Randomized, double-blind, placebo controlled trial of human recombinant growth hormone in patients with chronic heart failure
4. A placebo-contolled study of growth hormone in patients with congestive heart failure
5. The use of GH as a pharmacological agent
6. Insulin-like growth factor binding proteins: New proteins, new frontiers
7. Spontaneous growth hormone secretion by unstimulated human lymphocytes and the effects of GH-releasing hormone and somatostatin
8. Recombinant human growth hormone, insulin-like growth factor-1 and combination therapy in AIDS associated with wasting. A randomized, double-blind, placebo-controlled trial
9. Frailty and disability: Can growth hormone or other trophic agents make a difference?
10. Effects of recombinanat human growth hormone on donor site healing in severely burned children
11. GH administration and discontinuation in healthy elderly men: Body composition, GH-related serum markers, resting heart rate and resting oxygen uptake
12. Catabolism in chronic heart failure
13. Progressive cardiac dysfunction and fibrosis in the cardiomyopathic hamster and effects of growth hormone and angiotensin-converting enzyme inhibition
14. Markedly reduced insulin-like growth factor-1 in the acute phase of myocardial infarction
15. Epidemiology of osteoporosis
16. Skeletal effects of growth hormone and IGF-1 in adults
17. Growth hormone-releasing substances: Types and their receptors
18. Growth hormone receptor and cytokine family signaling
19. Structure and regulation of the human growth hormone-releasing hormone receptor gene
20. Growth hormone receptors on thymocytes and splenocytes from rats
21. Immune-enhancing effect of a growth hormone secretagogue
22. Interrelationships between sleep and the somatotropic axis
23. TNF-α down-regulates murine hepatic growth hormone receptor expression by inhibiting Sp1 and Sp3 binding
24. Protein metabolism and the use of growth hormone and insulin-like growth factor-1 in the critically ill patient
25. Growth factor insensitivity in renal failure
26. Acquired growth hormone resistance in patients with chronic heart failure: Implications for therapy with growth hormone
27. The pharmacokinetics of free insulin-like growth factor-1 in healthy male subjects
28. Pharmacokinetics of human growth hormone-releasing hormone in normal men after intravenous administration of large bolus doses
29. Elements in the pathophysiology of diminished growth hormone secretion in aging humans
30. Current management of acromegaly
31. The effect of GHRH on somatotrope hyperplasia and tumor formation in the presence and absence of GH signaling
32. Antitumorigenic actions of growth hormone-releasing hormone antagonists
33. Insulin-like growth factor-1 and prostate cancer
34. Growth hormone, body composition and aging
35. Detection of premature atherosclerosis by high-resolution ultrasonography in symptom-free hypopituitary adults